Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reltecimod in Necrotizing Soft Tissue Infections
NCT02469857Phase 3Completed
- Sponsor
- Atox Bio
- Start
- Dec 2015
- Primary completion
- Aug 2019
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of reltecimod in necrotizing soft tissue infection (NSTI), sponsored by Atox Bio. Started Dec 2015; status: completed.
02
Drugs
reltecimod
03
Conditions
necrotizing soft tissue infection (NSTI)
Beyond the preview
Go deeper on NCT02469857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469857.